Prothrombin Complex Concentrates for Clinical Use1
Open Access
- 12 November 1981
- journal article
- review article
- Published by Wiley in Vox Sanguinis
- Vol. 41 (5-6) , 257-273
- https://doi.org/10.1111/j.1423-0410.1981.tb01048.x
Abstract
Prothrombin complex concentrates prepared for clinical use are reviewed with emphasis on frequently observed adverse reactions such as viral hepatitis and thromboembolic complications. Preparation procedures and quality control are described briefly, and the use of these concentrates in the treatment of hemophilia A patients who develop factor VIII inhibitors is also described. The causes of and methods for the detection of potential thrombogenicity are discussed and suggestions which may result in a safer product are made.Keywords
This publication has 116 references indexed in Scilit:
- Hepatitis, Type B in HaemophiliacsScandinavian Journal of Haematology, 2009
- Hepatitis B VaccineNew England Journal of Medicine, 1980
- Efficacy of Prothrombin-Complex Concentrates in Hemophiliacs with Antibodies to Factor VIIINew England Journal of Medicine, 1980
- Use of Hepatitis B Immune Globulin: Reassessment NeededNew England Journal of Medicine, 1978
- Transfusions and Hepatitis: Update in '78New England Journal of Medicine, 1978
- Activated F IX Concentrate (FEIBA) Used in the Treatment of Haemophilic Patients with Antibody to F VIIIActa Medica Scandinavica, 1978
- Prothrombin complex concentrate (Konyne) in the treatment of hemophilic patients with factor VIII inhibitorsThe Journal of Pediatrics, 1976
- Factor VIII inhibitor following surgery for epidural hemorrhage in hemophilia: Successful therapy with a concentrate containing factors II, VII, IX, and XThe Journal of Pediatrics, 1976
- Reduction of post-transfusion hepatitis by exclusion of Australia antigen from donor blood in an urban public hospitalThe Lancet Healthy Longevity, 1974
- Contributions to the Optimal Use of Human BloodVox Sanguinis, 1973